H
Hua Medicine
HKEX:2552
Hua Medicine
HKEX:2552
Price:
3.35
HKD
-0.89%
Market Closed
Market Cap:
HK$3.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hua Medicine
Short-Term Investments
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Hua Medicine
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hua Medicine
HKEX:2552
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Short-Term Investments
¥17.6m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Short-Term Investments
¥113.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Short-Term Investments
¥4.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
4%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Short-Term Investments
¥2.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
21%
|
CAGR 10-Years
116%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Short-Term Investments
¥4.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
88%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Hua Medicine
Glance View
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
Intrinsic Value
7.29
HKD
Undervaluation 54%
H
